Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum.

Abstract

FASTPlaque technology applied directly to smear-positive sputum offers performance comparable to conventional methods, with results available in 2 days instead of weeks to months. The test may form a useful part of DOTS-Plus programmes to combat multidrug-resistant tuberculosis, improving patient prognosis and reducing ongoing transmission of disease. It does not require specialised equipment, making it appropriate for high-burden countries.